Advancing Next-Generation Infection Control Solutions
A Focused Pipeline Targeting Critical Unmet Needs in Infection Management
Our development programs address the limitations of conventional antimicrobials through proprietary HOCl-based chemistries that remain stable and effective in challenging clinical environments—including the presence of blood serum, biofilms, and organic matter.
Strategic Focus Areas
Our pipeline addresses infection challenges across three critical areas where conventional antimicrobials demonstrate significant limitations.
Pulmonary & Respiratory Infections
- Maintains efficacy in presence of serum and mucus
- Licensed to SpectrumX for UK/European markets
- Does not promote antimicrobial resistance
Wound Care & Surgical Applications
- Effective at >50% dilution with wound exudate
- Supports healing in chronic and acute wounds
- Targets surgical site infections and burn care
Hand Hygiene & Skin Antisepsis
- Eradicates C. difficile spores in 15-30 seconds
- Improved compliance through skin tolerability
- Suitable for surgical hand prep and clinical use
Lead Drug Candidate
SPX-001
Broad-Spectrum Pulmonary Antimicrobial
SPX-001 is a broad-spectrum antiviral and antibacterial drug candidate optimized for the treatment of pulmonary infections. Building on the validated SPC-069 chemistry, SPX-001 delivers unmatched efficacy in the presence of serum and mucus—the primary factors that limit conventional HOCl-based therapies in respiratory applications.
Key differences:
- Effective against both viral and bacterial respiratory pathogens
- Maintains antimicrobial activity in 5% serum and pulmonary mucus
- Does not promote antimicrobial resistance
- Designed for inhalation delivery
Phase:
Preclinical optimization
Partnership:
Licensed to SpectrumX (UK/Europe)
Indication:
Hospital-acquired pneumonia, VAP
Target Market:
Hospital ICUs, respiratory care units
Addressing the growing burden of hospital-acquired respiratory infections, where antibiotic resistance and limited treatment options create urgent clinical need.
Supporting Pipeline Programs
Advanced Wound Biofilm Eradication
Next-generation formulations designed to penetrate and eliminate established biofilms in chronic and acute wounds. Our proprietary chemistry maintains efficacy even at >50% dilution with wound exudate.
Target Applications
- Chronic wounds
- Surgical site infections
- Burn care
- Diabetic ulcers
Learn More →
Surgical Hand Antisepsis
Enhanced hand hygiene formulations that combine rapid microbial kill with sustained residual activity, supporting compliance through improved skin tolerability.
Target Applications
- Surgical hand preparation
- Clinical hand hygiene
- Infection prevention protocols
- Healthcare worker safety
Learn More →
Medical Device Disinfection
Hard surface and medical device sterilization platforms with rapid action against spores and biofilms, even at >98% dilution.
Target Applications
- CPAP devices
- Respiratory equipment
- Reusable medical instruments
- Healthcare facility surfaces
Learn More →
Key Milestones in Pipeline Development
Our timeline highlights essential milestones in the development of cutting-edge solutions for infection control. Each step showcases our commitment to advancing medical devices and therapeutics, ensuring better outcomes in healthcare settings.
Lead Drug Candidate
Disciplined Path to Market
Regulatory Excellence Through Experience
We advance pipeline programs through clearly defined regulatory pathways, leveraging our team’s extensive experience in FDA 510(k) submissions, CE Mark certifications, and clinical trial design.
Regulatory Achievements
- FDA-registered GMP manufacturing facility
- Multiple 510(k) clearances achieved
- CE Mark approvals for European markets
- Established quality systems and regulatory compliance infrastructure
Every development program is designed with regulatory requirements in mind from inception. We maintain close communication with regulatory authorities, conduct robust preclinical studies, and ensure manufacturing processes meet the highest quality standards.
Principles Driving Our Mission
At Spectrum Antimicrobials, we are guided by unwavering commitment to scientific rigor, patient-centered innovation, responsible stewardship, and transparent collaboration.
Lead Drug Candidate
Collaborate on Next-Generation Solutions
We seek strategic partners who share our commitment to advancing infection control through rigorous science and clinical evidence. Whether you’re interested in co-development, licensing, or distribution partnerships, we welcome conversations with organizations positioned to bring innovative solutions to market.
Regulatory Achievements
- Access to differentiated HOCl platform technology
- Established regulatory and manufacturing infrastructure
- Clinical and scientific expertise
- Finished product supply or technology transfer options
Partnership Types
- Licensing agreements for specific territories or applications
- Co-development partnerships for new indications
- Distribution partnerships in key markets
- Contract manufacturing arrangements
Advancing Infection Control Through Chemistry
Our proprietary platforms deliver what conventional antimicrobials cannot: sustained efficacy in the presence of organic matter, rapid action against resistant pathogens and spores, and no promotion of antimicrobial resistance.
Key Platform Advantages
- Effective against gram-positive and gram-negative bacteria, including resistant strains
- Broad-spectrum activity against viruses, fungi, mold, and spores
- Maintains stability and efficacy in 5% serum—overcoming traditional HOCl limitations
- Proven biofilm eradication at dilutions exceeding 98%
- Freeze-stable formulations enabling global distribution
- Non-toxic, safe for repeated use on skin and tissues
Scientific Validation: Our technology has been validated through independent laboratory testing, demonstrating superior performance compared to standard HOCl formulations and conventional disinfectants.
Let's advance infection care together
